Full Length Research Paper
References
|
Afonso A, Hunt P, Cheesman S, Alves AC, Cunha CV, do Rosario V, Cravo P (2006). Malaria parasites can develop stable resistance to artemisinin but lack mutations in candidate genes atp6 (encoding the sarcoplasmic and endoplasmic reticulum Ca2+ ATPase), tctp, mdr1, and cg10. Antimicrob. Agents Chemother. 50:480-489. Crossref |
||||
|
Carlton JM, Hayton K, Cravo, PV, Walliker D (2001). Of mice and malaria mutants: unraveling the genetics of drug resistance using rodent malaria models. Trends Parasit. 17:236-242. Crossref |
||||
|
Cravo PV, Carlton JM., Hunt PI, Bisoni L., Padua RA, Walliker D (2003). Genetics of mefloquine resistance in the rodent malaria parasite P. chabaudi. Antimicrob. Agents Chemother. 47:709-718. Crossref |
||||
|
Eastman RT, White J, Hucke O, Yokoyama K, Verlinde CLMJ, Hast MA, Beese LS, Gelb MH, Rathod PK, Van Voorhis WC (2005). Resistance to a protein farnesyltransferase inhibitor in P. falciparum. J. Biol. Chem. 280:13554-13559. Crossref |
||||
|
Gervais GW, Trujillo K, Robinson BL, Peters W, Serrano AE (1999). P.berghei: identification of an mdr-like gene associated with drug resistance. J. Exp. Parasitol. 91:86-92. Crossref |
||||
|
Hastings IM (2004). The origins of antimalarial drug resistance. Trends Parasitol. 20:512-518. Crossref |
||||
|
Hunt P1, Martinelli A, Fawcett R, Carlton J, Carter R, Walliker D (2004b). Gene synteny and chloroquine in Plasmodium chabaudi. Mol. Biochem. Parasitol. 136(2):157-164. Crossref |
||||
|
Hunt PI, Cravo PV, Donleavy, Carlton JM, Walliker D (2004a). Chloroquine resistance in Plasmodium chabaudi: are chloroquine-resistance transporter (crt) and multi-drug resistance (mdr1) orthologues involved? Mol. Biochem. Parasitol. 133:27-35. Crossref |
||||
|
Hunt P, Afonso A, Creasey A, Culleton R, Sidhu AB, Logan J, Valderramos SG, McNae I, Cheesman S, do Rosario V, Carter R, Fidock DA, Cravo P (2007). Gene encoding a deubiquitinating enzyme is mutated in artesunate- and chloroquine-resistant rodent malaria parasites. Mol. Microb. 65:27-40 Crossref |
||||
|
Jiang H, Patel JJ, Yi M, Mu J, Ding J, Stephens R, Cooper RA, Ferdig MT, Su XZ (2008). Genome-wide compensatory changes accompany drug- selected mutations in the Plasmodium falciparum crt gene. PLoS One 3(6):2484. Crossref |
||||
|
Kiboi DM, Irungu BN, Langa BT, Wittlin S, Brun R, Chollet J, Abiodun O, Nganga JK, Nyambati VC, S, Rukunga GM, Bell A, Nzila A (2009). Plasmodium berghei ANKA: Selection of resistance to piperaquine and lumefantrine in a mouse model. J. Exp. Parasitol. 122:196-202. Crossref |
||||
| Kiboi DM, Irungu BN, Langa BT, Nganga JK, Nyambati VCS (2009). Cross resistance studies. Unpublished data. | ||||
|
Li GD (1985). Development of a piperaquine-resistant line of Plasmodium berghei K173 strain. Yao Xue Xue Bao 20:412-417. Pubmed |
||||
| Li GD, Qu FY, Chen L (1985). Development of pipraquine-resistant line of Plasmodium berghei ANKA strain. Chin. J. Prev. Treat. Parasit. Dis. 3:189-192. | ||||
|
Marsh K (1998). Malaria disaster in Africa. Lancet 352:924-925. Crossref |
||||
|
Merkli B, Richle RW (1980). Studies on the resistance to single and combined antimalarial in the Plasmodium berghei mouse model. Acta Trop. 37:228-231. Pubmed |
||||
|
Nosten F, White NJ (2007). Artemisinin-based combination treatment of falciparum malaria. Am. J. Trop. Med. Hyg. 77:181-192. Pubmed |
||||
|
Nzila A, Mwai L (2010). In vitro selection of P. falciparum drug-resistant parasite lines. J. Antimicrob. Chemother. 65 (3):390-398. Crossref |
||||
|
Nzila AM, Nduati E, Mberu EK, Hopkins SC, Monks SA, Winstanley PA, Watkins WM (2000). Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate Pyrimethamine/Sulfadoxine compared with the shorter-acting chlorproguanil/dapsone on Kenyan Plasmodium falciparum. J. Infect. Dis. 181:2023-2028 Crossref |
||||
|
Peters W (1975). The chemotherapy of rodent malaria, XXII. The value of drug-resistant strains of P. berghei in screening for blood schizontocidal activity. Ann. Trop. Med Parasitol. 69:155-171. Pubmed |
||||
|
Peters W (1999). The chemotherapy of rodent malaria. LVII. Drug combinations to impede the selection of drug resistance, Part 1: which model is appropriate? Ann.Trop. Med. Parasitol. 93:569-587. Crossref |
||||
|
Peters W, Robinson BL (1992). The chemotherapy of rodent malaria. XLVII. Studies on pyronaridine and other Mannich base antimalarials. Ann. Trop. Med. Parasitol. 86:455-465. Pubmed |
||||
|
Peters W, Robinson BL (1999). The chemotherapy of rodent malaria. LVI. Studies on the development of resistance to natural and synthetic endoperoxides. Ann. Trop. Med. Parasitol. 93: 325-329. Crossref |
||||
|
Puri SK, Chandra, R (2006). Plasmodium vinckei: selection of a strain exhibiting stable resistance to arteether. J. Exp. Parasitol. 114:129-132. Crossref |
||||
|
Ramharter M1, Kurth F, Schreier AC, Nemeth J, Glasenapp Iv, Bélard S, Schlie M, Kammer J, Koumba PK, Cisse B, Mordmüller B, Lell B, Issifou S, Oeuvray C, Fleckenstein L, Kremsner PG (2008). Fixed-dose pyronaridine-artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon. J. Infect. Dis. 198:911-919. Crossref |
||||
|
Rathod PK, McErlean T, Lee PC (1997). Variations in frequencies of drug resistance in Plasmodium falciparum. Proc. Natl. Acad. Sci. USA 94: 9389 -9393. Crossref |
||||
|
Rosario VE (1981). Cloning of naturally occurring mixed infections of malaria parasites. Science 212(4498):1037-1038. Crossref |
||||
| Sang HP, Pradeep K (2010). Absorption, Distribution, Excretion, and pharmacokinetics of 14 C- Pyronaridine Tetraphosphate in Male and Female Sprague-Dawley Rats. J. Biomed. Biotechnol. 168:321-340. | ||||
| Shao BR (1990). A review of antimalarial drug pyronaridine. Chin. Med J. 103:428-434. | ||||
|
Shao BR, Ye XY (1986). Delay in emergence of resistance to pyronaridine phosphate in Plasmodium berghei (in Chinese). Zhongguo Yao Li Xue Bao 7:463-467. Pubmed |
||||
|
Sisowath C, Ferreira PE, Bustamante LY, Dahlstrom S, Martensson A, Bjorkman A, Krishna S, Gil JP (2007). The role of pfmdr1 in Plasmodium falciparum tolerance to artemether-lumefantrine in Africa. Trop. Med. Int. Health 12:736-742. Crossref |
||||
|
Tona L, Mesia K, Ngimbi NP, Chrimwami B, Okond'ahoka K, Cimanga T, de Bruyne S, Apers N, Hermans J, Totte L, Pieters AJ (2001). In-vivo antimalarial activity of Cassia occidentalis, Morinda morindoides and Phyllanthus niruri. Ann. Trop. Med. Parasitol. 95:47-57. Crossref |
||||
|
Vivas L, Rattray L, Stewart L, Bongard E, Robinson B, Peters W, Croft SL (2008). Anti-malarial efficacy of pyronaridine and artesunate in combination in vitro and in vivo. Acta Trop. 105:222-228. Crossref |
||||
|
Watkins WM, Mosobo M (1993). Treatment of P. falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life. Am. J. Trop. Med. Hyg. 87:75-78. Crossref |
||||
|
White NJ (2004). Antimalarial drug resistance. J. Clin. Invest. 113:1084-1092 Crossref |
||||
| World Health Organization (WHO) (2003). Fourth update on long-lasting insecticidal nets: current status and programmatic issues. Insecticide-treated mosquito net interventions: A manual for national control programme managers. Roll Back Malaria. Geneva. | ||||
| World Health Organization (WHO) (2006). Guidelines for the treatment of malaria. WHO Library Cataloguing-in-Publication Data. | ||||
|
Xiao SH, Yao JM, Utzinger YC, Chollet J, Marcel T (2004). Selection and reversal of P. berghei resistance in the mouse model following repeated high doses of artemether. Parasitol. Res. 92:215-219. Crossref |
||||
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
